Truvestments Capital’s Tvardi Therapeutics TVRD Stock Holding History

Truvestments Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13	Hold	4	–	–	﹤0.01%	1165
2025 Q4	$17	Hold	4	–	–	﹤0.01%	1019
2025 Q3	$156	Hold	4	–	–	﹤0.01%	996
2025 Q2	$93	Buy	+4	New	+$95	﹤0.01%	932
2025 Q1	–	Sell	-8	Closed	-$141	–	1174
2024 Q4	$141	Buy	8 +3	+60%	+$33	﹤0.01%	981
2024 Q3	$54	Buy	+5	New	+$59	﹤0.01%	920
2024 Q2	–	Sell	-5	Closed	-$160	–	717
2024 Q1	$160	Hold	5	–	–	﹤0.01%	707
2023 Q4	$131	Hold	5	–	–	﹤0.01%	776
2023 Q3	$296	Hold	5	–	–	﹤0.01%	659
2023 Q2	$498	Hold	5	–	–	﹤0.01%	656
2023 Q1	$864	Sell	5 -2	-29%	-$670	﹤0.01%	613
2022 Q4	$2.57K	Hold	7	–	–	﹤0.01%	678
2022 Q3	$2K	Hold	7	–	–	﹤0.01%	578
2022 Q2	$2K	Buy	+7	New	+$2.46K	﹤0.01%	584
2022 Q1	–	Sell	-7	Closed	-$3K	–	578
2021 Q4	$3K	Hold	7	–	–	﹤0.01%	539
2021 Q3	$4K	Hold	7	–	–	﹤0.01%	490
2021 Q2	$3K	Hold	7	–	–	﹤0.01%	528
2021 Q1	$5K	Buy	7 +1	+17%	+$685	﹤0.01%	527
2020 Q4	$3K	Buy	+6	New	+$3.15K	﹤0.01%	537
2020 Q3	–	Sell	-6	Closed	-$3K	–	577
2020 Q2	$3K	Buy	+6	New	+$3.31K	﹤0.01%	497
2020 Q1	–	Hold	0	–	–	–	557
2019 Q4	–	Sell	-10	Closed	-$7K	–	628
2019 Q3	$7K	Sell	10 -1	-9%	-$831	﹤0.01%	542
2019 Q2	$9K	Hold	11	–	–	0.01%	545
2019 Q1	$8K	Buy	+11	New	+$6.58K	0.01%	549
2018 Q3	$10K	Buy	+12	New	+$8.66K	﹤0.01%	644

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Truvestments Capital's TVRD Position: Q1 2026 in Review

Truvestments Capital held its Tvardi Therapeutics (TVRD) position steady in Q1 2026 at 4 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Truvestments Capital first reported a position in TVRD in Q3 2018 and has held it in 24 quarters since. The position peaked at $10K in Q3 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

Truvestments Capital held 4 shares of Tvardi Therapeutics worth $13 as of Q1 2026.
Truvestments Capital left its Tvardi Therapeutics share count unchanged in Q1 2026.
Tvardi Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1165 holding.
Truvestments Capital first reported a position in Tvardi Therapeutics in Q3 2018 and has held it in 24 quarters since.
Truvestments Capital's Tvardi Therapeutics position peaked at $10K in Q3 2018.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.